Trials / Unknown
UnknownNCT04179084
Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Chinese PLA General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single center, investigator initiated phase II clinical study to evaluate the efficacy and safety of fruquintinib plus Sintilimab as third-line therapy for colorectal cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | fruquintinib | 5mg qd, 2weeks on, 1week off |
| DRUG | Sintilimab | 200mg q3w |
Timeline
- Start date
- 2019-08-28
- Primary completion
- 2020-03-01
- Completion
- 2020-05-01
- First posted
- 2019-11-26
- Last updated
- 2019-11-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04179084. Inclusion in this directory is not an endorsement.